Impact of universal hepatitis B virus (HBV) screening using chemotherapy orders on the HBV reactivation in cancer patients.
| Title: | Impact of universal hepatitis B virus (HBV) screening using chemotherapy orders on the HBV reactivation in cancer patients. |
|---|---|
| Authors: | Marty, Céline1 (AUTHOR), Adam, Jean-Philippe2,3 (AUTHOR) jean-philippe.adam.chum@ssss.gouv.qc.ca, Martel-Laferrière, Valérie3,4,5 (AUTHOR), Doucet, Stéphane3,6 (AUTHOR), Martel, Dominic2,3 (AUTHOR) |
| Source: | Supportive Care in Cancer. Aug2024, Vol. 32 Issue 8, p1-8. 8p. |
| Abstract: | Introduction: Hepatitis B virus (HBV) reactivation (HBVr) induced by chemotherapy in patients with resolved or chronic infection can lead to severe consequences. Despite recommendations, rates of HBV screening before chemotherapy are low due to poor recognition of risk factors by clinicians. The aim of the study is to assess whether routine HBV screening using universal HBV screening on chemotherapy orders (CO) could reduce HBVr incidence. Methods: This is a 1-year retrospective single-center observational study of patients who received intravenous chemotherapy post implementation of CO. We compared the incidence of HBVr in three groups of patients: those screened through CO (group 1), those screened by the medical team (group 2), and those not screened (group 3). Results: On a total of 1374 patients, 179 of 206 patients were screened as requested on CO (group 1) and 421 by the medical team (group 2), whereas 747 patients were not screened (group 3). Only one HBVr occurred, and no difference was seen on the incidence of HBVr between group 1 and group 3 (0% vs 0.1%; p = 1.00), probably because of a lack of follow-up after chemotherapy. Follow-up for HBVr was imperfect in group 1 and group 2 (16.7% vs 5.6%; p = 0.32). Screening was done for 92% of patients on anti-CD20 therapy. In group 3, 89 patients had ALT elevation during chemotherapy but only 17 (19%) were tested for HBVr. Conclusion: Systematic HBV detection requested on CO is an effective way to obtain a high percentage of patients with adequate screening, particularly when chemotherapy is at high risk of HBVr. Nevertheless, this screening method do not guarantee optimal follow-up and requires improvements. [ABSTRACT FROM AUTHOR] |
| Copyright of Supportive Care in Cancer is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Academic Search Complete |
| FullText | Text: Availability: 0 CustomLinks: – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:a9h&genre=article&issn=09414355&ISBN=&volume=32&issue=8&date=20240801&spage=1&pages=1-8&title=Supportive Care in Cancer&atitle=Impact%20of%20universal%20hepatitis%20B%20virus%20%28HBV%29%20screening%20using%20chemotherapy%20orders%20on%20the%20HBV%20reactivation%20in%20cancer%20patients.&aulast=Marty%2C%20C%C3%A9line&id=DOI:10.1007/s00520-024-08750-6 Name: Full Text Finder (for New FTF UI) (s8985755) Category: fullText Text: Find It @ SCU Libraries MouseOverText: Find It @ SCU Libraries |
|---|---|
| Header | DbId: a9h DbLabel: Academic Search Complete An: 178673541 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Impact of universal hepatitis B virus (HBV) screening using chemotherapy orders on the HBV reactivation in cancer patients. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Marty%2C+Céline%22">Marty, Céline</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Adam%2C+Jean-Philippe%22">Adam, Jean-Philippe</searchLink><relatesTo>2,3</relatesTo> (AUTHOR)<i> jean-philippe.adam.chum@ssss.gouv.qc.ca</i><br /><searchLink fieldCode="AR" term="%22Martel-Laferrière%2C+Valérie%22">Martel-Laferrière, Valérie</searchLink><relatesTo>3,4,5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Doucet%2C+Stéphane%22">Doucet, Stéphane</searchLink><relatesTo>3,6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Martel%2C+Dominic%22">Martel, Dominic</searchLink><relatesTo>2,3</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Supportive+Care+in+Cancer%22">Supportive Care in Cancer</searchLink>. Aug2024, Vol. 32 Issue 8, p1-8. 8p. – Name: Abstract Label: Abstract Group: Ab Data: Introduction: Hepatitis B virus (HBV) reactivation (HBVr) induced by chemotherapy in patients with resolved or chronic infection can lead to severe consequences. Despite recommendations, rates of HBV screening before chemotherapy are low due to poor recognition of risk factors by clinicians. The aim of the study is to assess whether routine HBV screening using universal HBV screening on chemotherapy orders (CO) could reduce HBVr incidence. Methods: This is a 1-year retrospective single-center observational study of patients who received intravenous chemotherapy post implementation of CO. We compared the incidence of HBVr in three groups of patients: those screened through CO (group 1), those screened by the medical team (group 2), and those not screened (group 3). Results: On a total of 1374 patients, 179 of 206 patients were screened as requested on CO (group 1) and 421 by the medical team (group 2), whereas 747 patients were not screened (group 3). Only one HBVr occurred, and no difference was seen on the incidence of HBVr between group 1 and group 3 (0% vs 0.1%; p = 1.00), probably because of a lack of follow-up after chemotherapy. Follow-up for HBVr was imperfect in group 1 and group 2 (16.7% vs 5.6%; p = 0.32). Screening was done for 92% of patients on anti-CD20 therapy. In group 3, 89 patients had ALT elevation during chemotherapy but only 17 (19%) were tested for HBVr. Conclusion: Systematic HBV detection requested on CO is an effective way to obtain a high percentage of patients with adequate screening, particularly when chemotherapy is at high risk of HBVr. Nevertheless, this screening method do not guarantee optimal follow-up and requires improvements. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Supportive Care in Cancer is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=a9h&AN=178673541 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s00520-024-08750-6 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 8 StartPage: 1 Titles: – TitleFull: Impact of universal hepatitis B virus (HBV) screening using chemotherapy orders on the HBV reactivation in cancer patients. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Marty, Céline – PersonEntity: Name: NameFull: Adam, Jean-Philippe – PersonEntity: Name: NameFull: Martel-Laferrière, Valérie – PersonEntity: Name: NameFull: Doucet, Stéphane – PersonEntity: Name: NameFull: Martel, Dominic IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 08 Text: Aug2024 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 09414355 Numbering: – Type: volume Value: 32 – Type: issue Value: 8 Titles: – TitleFull: Supportive Care in Cancer Type: main |
| ResultId | 1 |